<?xml version='1.0' encoding='utf-8'?>
<document id="11336328"><sentence text="Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer."><entity charOffset="37-47" id="DDI-PubMed.11336328.s1.e0" text="paclitaxel" /><entity charOffset="68-77" id="DDI-PubMed.11336328.s1.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.11336328.s1.e0" e2="DDI-PubMed.11336328.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s1.e0" e2="DDI-PubMed.11336328.s1.e1" /></sentence><sentence text="To establish the toxicities and maximum tolerated dose of paclitaxel given over 3 h in combination with cisplatin, to determine the pharmacokinetic profiles of these two drugs and to observe their antitumor activity, we conducted a combination phase I study in non-small cell lung cancer"><entity charOffset="58-68" id="DDI-PubMed.11336328.s2.e0" text="paclitaxel" /><entity charOffset="104-113" id="DDI-PubMed.11336328.s2.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.11336328.s2.e0" e2="DDI-PubMed.11336328.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s2.e0" e2="DDI-PubMed.11336328.s2.e1" /></sentence><sentence text="" /><sentence text="Patients received paclitaxel doses of 150-210 mg/m2 given over 3 h and cisplatin doses of 60-80 mg/m2 as a 1 h infusion 2 h after the end of the paclitaxel infusion"><entity charOffset="18-28" id="DDI-PubMed.11336328.s4.e0" text="paclitaxel" /><entity charOffset="71-80" id="DDI-PubMed.11336328.s4.e1" text="cisplatin" /><entity charOffset="145-155" id="DDI-PubMed.11336328.s4.e2" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.11336328.s4.e0" e2="DDI-PubMed.11336328.s4.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s4.e0" e2="DDI-PubMed.11336328.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11336328.s4.e0" e2="DDI-PubMed.11336328.s4.e2" /><pair ddi="false" e1="DDI-PubMed.11336328.s4.e1" e2="DDI-PubMed.11336328.s4.e1" /><pair ddi="false" e1="DDI-PubMed.11336328.s4.e1" e2="DDI-PubMed.11336328.s4.e2" /></sentence><sentence text="" /><sentence text="A total of 25 patients with previously untreated non-small cell lung cancer were enrolled" /><sentence text=" Granulocytopenia was the most frequent hematological toxicity and the most prominent non-hematological toxicity was sensory dominant neuropathy" /><sentence text=" Two of six patients experienced dose limiting toxicities (leukopenia, infection and neuropathy) at a dose of paclitaxel 210 mg/m2 and cisplatin 60 mg/m2, which was considered the maximum tolerated dose"><entity charOffset="110-120" id="DDI-PubMed.11336328.s8.e0" text="paclitaxel" /><entity charOffset="135-144" id="DDI-PubMed.11336328.s8.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.11336328.s8.e0" e2="DDI-PubMed.11336328.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s8.e0" e2="DDI-PubMed.11336328.s8.e1" /></sentence><sentence text=" There were seven partial responses among 24 evaluable patients, for an overall response rate of 29%" /><sentence text=" The median survival time was 341 days and the 1 year survival rate was 45" /><sentence text="8%" /><sentence text=" As the paclitaxel pharmacokinetic parameters in this study were consistent with those of our previous single agent study, we found no significant drug-drug interaction between the 3 h infusion paclitaxel and cisplatin"><entity charOffset="8-18" id="DDI-PubMed.11336328.s12.e0" text="paclitaxel" /><entity charOffset="194-204" id="DDI-PubMed.11336328.s12.e1" text="paclitaxel" /><entity charOffset="209-218" id="DDI-PubMed.11336328.s12.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.11336328.s12.e0" e2="DDI-PubMed.11336328.s12.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s12.e0" e2="DDI-PubMed.11336328.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11336328.s12.e0" e2="DDI-PubMed.11336328.s12.e2" /><pair ddi="false" e1="DDI-PubMed.11336328.s12.e1" e2="DDI-PubMed.11336328.s12.e1" /><pair ddi="false" e1="DDI-PubMed.11336328.s12.e1" e2="DDI-PubMed.11336328.s12.e2" /></sentence><sentence text="" /><sentence text="The recommended doses for further study are determined to be paclitaxel 180 mg/m2 and cisplatin 80 mg/m2"><entity charOffset="61-71" id="DDI-PubMed.11336328.s14.e0" text="paclitaxel" /><entity charOffset="86-95" id="DDI-PubMed.11336328.s14.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.11336328.s14.e0" e2="DDI-PubMed.11336328.s14.e0" /><pair ddi="false" e1="DDI-PubMed.11336328.s14.e0" e2="DDI-PubMed.11336328.s14.e1" /></sentence><sentence text=" This is a well-tolerated and active regimen for non-small cell lung cancer" /><sentence text=" In view of the promising survival outcome, further evaluation in prospective randomized trials versus other regimens is warranted" /><sentence text="" /></document>